Haizhen (Jen) Wang, Ph.D., recently found out that her traditional R01 application for funding to the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), was converted to a more desirable R37 award totaling $344,000. The R37 affords Dr. Wang more time to progress the research while also building out a lab at MUSC Hollings Cancer Center. Investigating leukemia, Dr. Wang focuses her research on the complex biological communication between cancer cells and a patient’s healthy cells to help better treatment choices. With funds in hand, Dr. Wang’s mission now involves progressing her research uncovering the connection between cancer metabolism and cancer immunology. An expert in this topic, to date, her investigations reveal that cyclin-dependent kinase 6 (CDK6) could regulate leukemia and other cancers.
Finding better treatments for leukemia is top of mind for Dr. Wang. Caroline Wallace, writing for Medical University of South Carolina (MUSC), reports that Wang targets a particularly aggressive form of cancer of the immune cells in the blood known as T-cell acute lymphoblastic leukemia. With less than a 25% overall survival rate for re...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).